DOI:
10.1055/s-00000133
Gastroenterologie up2date
LinksClose Window
References
De Matteo RK, Owzar KR, Maki R. et al.
Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumour (GIST): North American intergroup phase III trial ACOSOG Z9001. ASCO Annual Meetings Proceedings Part I.
J Clin Oncol 2007; 25 (18 Suppl): 10 079-
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.